Sutro Biopharma. has been granted a patent for antibody conjugates targeting folate receptor alpha (FOLR1). These conjugates, which include trastuzumab variable light chains, are designed for therapeutic and diagnostic applications, featuring specific non-natural amino acids at designated sites. Methods for their production and use are also disclosed. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sutro Biopharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody conjugates targeting folate receptor alpha (folr1)
The patent US12071477B2 describes an innovative antibody conjugate that specifically targets the folate receptor alpha (FOLR1). This conjugate is characterized by a site-specific linkage to at least one payload moiety, which can include various non-natural amino acids and hemiasterlin residues. The claims detail the structural formulas of the antibody conjugate, emphasizing the inclusion of monoclonal antibodies, humanized antibodies, and antibody fragments. Additionally, the conjugate may incorporate non-natural amino acids, enhancing its therapeutic potential. The claims also specify various combinations of heavy and light chain complementarity-determining regions (CDRs), providing a comprehensive framework for the design of these antibody conjugates.
Furthermore, the patent outlines the potential applications of these antibody conjugates in pharmaceutical compositions, which may include excipients, carriers, or diluents to facilitate their use in therapeutic settings. The specificity of the antibody for FOLR1 suggests potential utility in targeting cancer cells that overexpress this receptor, thereby enhancing the efficacy of the payload moieties linked to the antibody. The extensive list of CDR sequences and structural variations indicates a robust approach to optimizing the performance of these conjugates in clinical applications. Overall, this patent presents a significant advancement in the field of targeted therapies, particularly in the context of cancer treatment.
To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
